Header Logo

Connection

Annette Langer-Gould to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications Annette Langer-Gould has written about Multiple Sclerosis.
Annette Langer-Gould
Connection Strength
23.223
Multiple Sclerosis
  1. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May; 11(3):e200211.
    View in: PubMed
    Score: 0.814
  2. Rituximab for Multiple Sclerosis: Hiding in Plain Sight Neurology. 2024 01 23; 102(2):e208063.
    View in: PubMed
    Score: 0.800
  3. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023 Nov; 10(6).
    View in: PubMed
    Score: 0.789
  4. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023 07; 10(4).
    View in: PubMed
    Score: 0.769
  5. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Netw Open. 2022 12 01; 5(12):e2248664.
    View in: PubMed
    Score: 0.744
  6. The Role of Diet in Multiple Sclerosis: Food for Thought. Neurology. 2023 Jan 24; 100(4):167-168.
    View in: PubMed
    Score: 0.738
  7. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022 05 03; 98(18):e1818-e1827.
    View in: PubMed
    Score: 0.715
  8. Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review. JAMA Neurol. 2021 12 01; 78(12):1515-1524.
    View in: PubMed
    Score: 0.694
  9. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021 04; 8(4):938-943.
    View in: PubMed
    Score: 0.662
  10. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
    View in: PubMed
    Score: 0.656
  11. An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis. Mult Scler. 2021 09; 27(10):1611-1614.
    View in: PubMed
    Score: 0.654
  12. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.622
  13. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020 05 05; 94(18):e1939-e1949.
    View in: PubMed
    Score: 0.620
  14. Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
    View in: PubMed
    Score: 0.616
  15. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019 09; 6(9):1905-1922.
    View in: PubMed
    Score: 0.591
  16. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019 Jun; 25(3):773-792.
    View in: PubMed
    Score: 0.584
  17. Vitamin D deficiency is an etiological factor for MS - No. Mult Scler. 2019 04; 25(5):639-641.
    View in: PubMed
    Score: 0.564
  18. MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. Nutrients. 2018 Feb 27; 10(3).
    View in: PubMed
    Score: 0.535
  19. Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis. Nutrients. 2018 Feb 07; 10(2).
    View in: PubMed
    Score: 0.533
  20. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study. Neurology. 2017 Sep 26; 89(13):1330-1337.
    View in: PubMed
    Score: 0.517
  21. Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurology. 2017 Aug 08; 89(6):563-569.
    View in: PubMed
    Score: 0.512
  22. Breastfeeding and Disease-Modifying Therapy for Multiple Sclerosis--Reply. JAMA Neurol. 2016 Apr; 73(4):480-1.
    View in: PubMed
    Score: 0.469
  23. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. PLoS One. 2016; 11(3):e0149094.
    View in: PubMed
    Score: 0.466
  24. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol. 2015 Oct; 72(10):1132-8.
    View in: PubMed
    Score: 0.453
  25. Association between vaccines and neuroinflammation-reply. JAMA Neurol. 2015 May; 72(5):605.
    View in: PubMed
    Score: 0.440
  26. Place of birth,age of immigration,and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord. 2015 Jan; 4(1):25-30.
    View in: PubMed
    Score: 0.430
  27. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec; 71(12):1506-13.
    View in: PubMed
    Score: 0.427
  28. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Oct 28; 83(18):1685.
    View in: PubMed
    Score: 0.425
  29. The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol. 2014 Jul; 261(7):1349-55.
    View in: PubMed
    Score: 0.410
  30. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014 Feb 25; 82(8):654-5.
    View in: PubMed
    Score: 0.403
  31. Spinal cord lesions and disability in Hispanics with multiple sclerosis. J Neurol. 2013 Nov; 260(11):2770-6.
    View in: PubMed
    Score: 0.390
  32. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013 May 07; 80(19):1734-9.
    View in: PubMed
    Score: 0.383
  33. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013 Feb 05; 80(6):548-52.
    View in: PubMed
    Score: 0.376
  34. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol. 2013 Nov; 149(2):244-50.
    View in: PubMed
    Score: 0.376
  35. Vitamin D levels in Hispanics with multiple sclerosis. J Neurol. 2012 Dec; 259(12):2565-70.
    View in: PubMed
    Score: 0.358
  36. Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses. Arch Neurol. 2011 Mar; 68(3):310-3.
    View in: PubMed
    Score: 0.322
  37. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010 Jul; 16(7):855-61.
    View in: PubMed
    Score: 0.312
  38. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009 Aug; 66(8):958-63.
    View in: PubMed
    Score: 0.292
  39. What went wrong in the natalizumab trials? Lancet. 2006 Mar 04; 367(9512):708-10.
    View in: PubMed
    Score: 0.233
  40. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S35-41.
    View in: PubMed
    Score: 0.214
  41. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023 07 01; 80(7):693-701.
    View in: PubMed
    Score: 0.194
  42. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023 05; 29(6):731-740.
    View in: PubMed
    Score: 0.191
  43. COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022 09; 9(9):1449-1458.
    View in: PubMed
    Score: 0.182
  44. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw Open. 2021 12 01; 4(12):e2136697.
    View in: PubMed
    Score: 0.174
  45. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.161
  46. Safety of potential breast milk exposure to IFN-ß or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.156
  47. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 07 02; 7(4).
    View in: PubMed
    Score: 0.155
  48. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020 05; 87(5):688-699.
    View in: PubMed
    Score: 0.154
  49. Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology. 2019 03; 30(2):230-233.
    View in: PubMed
    Score: 0.143
  50. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 03 05; 92(10):e1029-e1040.
    View in: PubMed
    Score: 0.143
  51. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
    View in: PubMed
    Score: 0.143
  52. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.
    View in: PubMed
    Score: 0.142
  53. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016 05; 22(6):801-9.
    View in: PubMed
    Score: 0.116
  54. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016 05; 22(6):810-6.
    View in: PubMed
    Score: 0.115
  55. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014 Jul 01; 71(7):891-5.
    View in: PubMed
    Score: 0.104
  56. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 May; 8(5):500-8.
    View in: PubMed
    Score: 0.045

© 2025 Kaiser Permanente